Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, placebo-controlled phase II clinical study of orelabrutinib in patients with Neuromyelitis Optica Spectrum Disorder

Next Previous
Trial Profile

Randomized, double-blind, placebo-controlled phase II clinical study of orelabrutinib in patients with Neuromyelitis Optica Spectrum Disorder

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orelabrutinib (Primary)
  • Indications Neuromyelitis optica
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 21 Aug 2022 Status changed from planning to recruiting, according to an InnoCare Pharma media release.
  • 03 Mar 2022 New trial record
  • 01 Mar 2022 According to an InnoCare Pharma media release, the China National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) for orelabrutinib to initiate this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top